Strong Specific Inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide i and III

Phytotherapy Research

Volumn 30, Issue 1, 2016, Pages 25-30

  Zhang, Qian ^a   Cao, Yun Feng ^b   Ran, Rui Xue ^c   Li, Rong Shan ^c   Wu, Xue ^a,d   Dong, Pei Pei ^e   Zhang, Yan Yan ^d,f   Hu, Cui Min ^c   Wang, Wei Ming ^a  

^a DALIAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

^f JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

atractylenolide I; atractylenolide III; drug drug interaction

Indexed keywords

ATRACTYLENOLIDE I; ATRACTYLENOLIDE III; GLUCURONOSYLTRANSFERASE; HYMECROMONE; ISOPROTEIN; LACTONE; RECOMBINANT PROTEIN; SESQUITERPENE; UGT2B7 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG INTERACTION; HUMAN; KINETICS; METABOLISM;

DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; KINETICS; LACTONES; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; SESQUITERPENES;

EID: 84954039605     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5496     Document Type: Article

References (20)

1. Aoshima N, Fujie Y, Itoh T, Tukey RH, Fujiwara R,. 2014. Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia. Sci Rep 4: 6343.
2. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C,. 2009. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37: 1793-1796.
3. Erichsen TJ, Aehlen A, Ehmer U, Kalthoff S, Manns MP, Strassburg CP,. 2010. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J Hepatol 52: 570-578.
4. Fang ZZ, He RR, Cao YF, et al., 2013. A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. J Lipid Res 54 (12): 3334-3344.
5. Gao X, Qu H, Ai CZ, et al., 2014. Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDPglucuronosyltransferases (UGTs) isoforms. Xenobiotica 26: 1-10.
6. Huang JM, Zhang GN, Shi Y, et al., 2014. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep 4: 3840.
7. Jia L, Hu C, Wang H, et al., 2015. Chirality influence of zaltoprofen towards UDP-glucuronosyltransferases (UGTs) inhibition potential. Chirality 27 (6): 359-363.
8. Jiang HM, Fang ZZ, Cao YF, et al., 2013. New insights for the risk of bisphenol A: inhibition of UDP-glucuronosyltransferases (UGTs). Chemosphere 93 (6): 1189-1193.
9. Kang TH, Bang JY, Kim MH, Kang IC, Kim HM, Jeong HJ,. 2011. Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway. Food Chem Toxicol 49 (2): 514-519.
10. Liang SC, Ge GB, Liu HX, et al., 2011. Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESIMS. J Pharm Biomed Anal 54: 236-241.
11. Liu H, Zhu Y, Zhang T, et al., 2013. Anti-tumor effects of atractylenolide I isolated from Atractylodes macrocephala in human lung carcinoma cell lines. Molecules 18 (11): 13357-13368.
12. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR,. 2007. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369: 498-511.
13. Shakibi R, Kamalidehghan B, Ahmadipour F, Meng GY, Houshmand M,. 2015. Prevalence of the UGT1A1 6 (c.211G>a) polymorphism and prediction of irinotecan toxicity in Iranian populations of different ethnicities. Chemotherapy 60 (5): 279-287.
14. Sun YX, Zhuo WY, Lin H, et al., 2015. The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res 114: 78-80.
15. Wang C, Wang S, Chen Q, He L,. 2008. A capillary gas chromatography-selected ion monitoring mass spectrometry method for the analysis of atractylenolide I in rat plasma and tissues, and application in a pharmacokinetic study. J Chromatogr B 863 (2): 215-222.
16. Wang C, Duan H, He L,. 2009. Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol 612 (1-3): 143-152.
17. Wang KT, Chen LG, Wu CH, Chang CC, Wang CC,. 2010. Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo. J Pharm Pharmacol 62 (3): 381-388.
18. Yuan L, Qian S, Xiao Y, Sun H, Zeng S,. 2015. Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. Biochem Pharmacol 95 (1): 58-70.
19. Zhao H, Ji ZH, Liu C, Yu XY,. 2015. Neuroprotection and mechanisms of atractylenolide III in preventing learning and memory impairment induced by chronic high-dose homocysteine administration in rats. Neuroscience 290: 485-491.
20. Zucker SD, et al., 2001. Mechanism of indinavirinduced hyperbilirubinemia. Proc Natl Acad Sci U S A 98: 12671-12676.